Genetic and Structural Analyses Reveal the Low Potential of the SARS-CoV-2 EG.5 Variant
Overview
Authors
Affiliations
The severe acute respiratory syndrome coronavirus 2 EG.5 lineage is the latest variant under monitoring, and it is generating significant concern due to its recent upward trend in prevalence. Our aim was to gain insights into this emerging lineage and offer insights into its actual level of threat. Both genetic and structural data indicate that this novel variant presently lacks substantial evidence of having a high capacity for widespread transmission. Their viral population sizes expanded following a very mild curve and peaked several months after the earliest detected sample. Currently, neither the viral population size of EG.5 nor that of its first descendant is increasing. The genetic variability appear to be flattened, as evidenced by its relatively modest evolutionary rate (9.05 × 10 subs/site/year). As has been observed with numerous prior variants, attributes that might theoretically provide advantages seem to stem from genetic drift, enabling the virus to continually adjust to its host, albeit without a clear association with enhanced dangerousness. These findings further underscore the necessity for ongoing genome-based monitoring, ensuring preparedness and a well-documented understanding of the unfolding situation.
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.
Guo H, Ha S, Botten J, Xu K, Zhang N, An Z Viruses. 2024; 16(5).
PMID: 38793580 PMC: 11125895. DOI: 10.3390/v16050697.
Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
Sil D, Gautam S, Saxena S, Joshi S, Kumar D, Mehta A Curr Drug Targets. 2024; 25(8):517-525.
PMID: 38726782 DOI: 10.2174/0113894501296586240430061915.
Scarpa F, Branda F, Petrosillo N, Ciccozzi M Infect Dis Rep. 2024; 16(2):289-297.
PMID: 38667750 PMC: 11050187. DOI: 10.3390/idr16020024.
Xue S, Han Y, Wu F, Wang Q Protein Cell. 2024; 15(6):403-418.
PMID: 38442025 PMC: 11131022. DOI: 10.1093/procel/pwae007.
Tang J, Xu Q, Zhu C, Xuan K, Li T, Li Q Vaccines (Basel). 2024; 12(2).
PMID: 38400158 PMC: 10893468. DOI: 10.3390/vaccines12020175.